Our COVID-19 solutions key facts...

We are committed to accelerating the development of COVID-19 vaccines and treatments, whilst ensuring the highest levels of safety and efficacy

gsk do more feel better live longer

23 September 2020, Update 7

...our science and technology

***What is an adjuvant?**

An adjuvant can be added to a vaccine to boost the body's immune response, which means less vaccine is needed for the same result. This is particularly important in a pandemic as more vaccine doses can be available to protect people around the world

COVID-19 virus



Our primary aim is to use our unique adjuvant technology* to develop multiple COVID-19 adjuvanted vaccines, so we are:

- **partnering with multiple companies and research groups across the world,** including China, North America and EU
- **combining our expertise and scale with Sanofi to develop an adjuvanted vaccine** which entered clinical trials in September 2020
- **planning to produce 1 billion vaccine adjuvant doses in 2021**

Committed to affordable pricing we do not expect to profit from our portfolio of collaborations for COVID-19 adjuvanted vaccines. Any short-term profit that may be generated will be invested in support of coronavirus related research and long-term pandemic preparedness

Committed to global access we will make our adjuvant available to the world's poorest countries, through donations and by working with global institutions that prioritise access

Collaborating with Vir Biotechnology to identify and accelerate new anti-viral antibodies which could be used as therapeutic or preventative options to fight this and future outbreaks. This is innovative technology using antibodies from SARS survivors. The first clinical trial started in August 2020 with initial results expected before end 2020, and further trials planned

Developing a rapid test to detect COVID-19 that uses patented technology and is reliable, fully disposable and easy-to-use at home

We have also reviewed our marketed medicines and pipeline to determine if any have potential activity against COVID-19 or to treat secondary complications

- Started a clinical trial to assess whether a monoclonal antibody in development can help treat patients who are affected by severe pulmonary COVID-19 related disease



...our existing products

Ensuring continuous supply of our medicines, vaccines and consumer healthcare products with 20,000 employees working in our manufacturing sites and R&D labs around the world

...our capabilities and expert facilities

Set up specialised laboratory space to help support national diagnostic testing in the UK and Belgium

Providing free curriculum linked STEM resources online in the UK and US, supporting teachers and parents whilst students are at home

...supporting frontline health workers

$10 million donation to WHO and the UN Foundation's COVID-19 Solidarity Response Fund to prevent, detect, and manage the pandemic in support of frontline health workers

Employee volunteering with over 260 scientists volunteering across EU, US and SA

Donated lab equipment, instruments, and scientific kits to support government testing and **over 800,000 PPE units** to protect frontline health workers in 34 countries

Over £13.3m in 49 countries donated to local charities and communities